Review
Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis

https://doi.org/10.1016/S0306-3623(96)00314-XGet rights and content

Abstract

  • 1.

    1. Pentoxifylline (PTX), a derivative of the methylxanthine theobromine, has been used for many years in the treatment of peripheral vascular diseases. Increased red blood cell flexibility, reduction of blood viscosity, and decreased potential of platelet aggregation are the basic actions of PTX, resulting in therapeutic benefits due to improved microcirculation and tissue oxygenation.

  • 2.

    2. PTX's generally accepted mechanism of action is the inhibition of phosphodiesterases, leading to increased intracellular levels of cyclic adenosine monophosphate (cAMP).

  • 3.

    3. A number of studies have shown PTX's effects on the cytokine network. The most relevant clinical results are the therapeutic benefits of PTX in attenuating the effects of tumor necrosis factor-α (TNF-α) in conditions such as septic shock.

  • 4.

    4. PTX also has been found to exert antifibrogenic actions, using cultured fibroblasts or animal models of fibrosis, including liver fibrosis.

  • 5.

    5. In hepatic stellate cell culture PTX has been shown to inhibit the basic reactions of liver fibrogenesis, being effective on cytokines and growth factors relevant in fibrogenesis of the liver, too.

  • 6.

    6. Therefore, PTX might be an effective drug with few side effects in the treatment of liver fibrosis. Further clinical studies have to be done to establish the real therapeutic benefits of PTX in liver fibrosis and cirrhosis.

References (194)

  • T.A. Bryce et al.

    Determination of oxpentifylline and a metabolite, 1-(5′-hydroxyhexyl)-3,7-dimethylxanthine, by gas-liquid chromatography using a nitrogen-selective detector

    J. Chromatogr

    (1980)
  • A. Casini et al.

    Regulation of undulin synthesis and gene expression in human fat storing cells by acetaldehyde and transforming growth factor-beta1—comparison with fibronectin

    Biochem. Biophys. Res. Commun.

    (1994)
  • C.C. Chao et al.

    Tumor necrosis factor-alpha mediates the releast of bioactive transforming growth factor-beta in murine microglial cell cultures

    Clin. Immunol. Immunopathol.

    (1995)
  • W. Chen et al.

    Inhibition in fat storing cell multiplication by a factor produced by normal cultured murine hepatocytes

    J. Hepatol.

    (1990)
  • M.J. Czaja et al.

    Prevention of carbon tetrachloride induced rat liver injury by soluble tumor necrosis factor receptor

    Gastroenterology

    (1995)
  • M.R. Duncan et al.

    Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation

    J. Invest. Dermatol.

    (1995)
  • F. Fazely et al.

    Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type I in human peripheral blood mononuclear cells and in cultured T cells

    Blood

    (1991)
  • W.J. Flynn et al.

    Pentoxifylline but not saralasin restores hepatic blood flow after resuscitation from hemorrhagic shock

    J. Surg. Res.

    (1991)
  • J.O. Funk et al.

    Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A

    Int. J. Immunopharmacol.

    (1995)
  • A. Geerts et al.

    Cell population kinetics of Kupffer cells during the onset of fibrosis in rat liver by chronic carbon tetrachloride administration

    J. Hepatol.

    (1988)
  • V. Glaser

    Gene transfer to the liver

    Molec. Med. Today

    (1996)
  • A.M. Gressner et al.

    Hyaluronic acid synthesis and secretion by rat liver fat storing cells (perisinusoidal lipocytes) in culture

    Biochem. Biophys. Res. Commun.

    (1988)
  • A.M. Gressner et al.

    Treatment of rat hepatocytes with transforming growth factor-betal increases their mitogenic activity for cultured fat storing cells

    Inter. Hepatol. Commun.

    (1995)
  • A.M. Gressner et al.

    Induction of rat liver parenchymal cell apoptosis by hepatic myofibroblasts via transforming growth factor beta

    Hepatology

    (1996)
  • M. Guido et al.

    Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy

    J. Hepatol.

    (1996)
  • C. Hoffmann et al.

    The relation between hepatocellular damage and activation of fat storing cell proliferation in vitro

    Inter. Hepatol. Commun.

    (1994)
  • N. Kawada et al.

    Effect of adrenomedullin on hepatic pericytes (stellate cells) of the rat

    FEBS Lett.

    (1994)
  • M.L. Alegre et al.

    Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome

    Transplantation

    (1991)
  • J.L. Ambrus et al.

    Hemorrheologic effects of metabolites of pentoxifylline (Trental)

    J. Med.

    (1995)
  • T. Andus et al.

    Cultured Ito cells of rat liver express the alpha2-macroglobulin gene

    Eur. J. Biochem.

    (1987)
  • P.P. Anthony et al.

    The morphology of cirrhosis

    J. Clin. Pathol.

    (1978)
  • D.M. Aviado et al.

    Pharmacology of pentoxifylline: a hemorrheologic agent for the treatment of intermittent claudication

    Angiology

    (1984)
  • D.M. Aviado et al.

    Pentoxifylline: a new drug for the treatment of intermittent claudication

    Pharmacotherapy

    (1984)
  • M.G. Bachem et al.

    The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocytederived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells

    J. Clin. Chem. Clin. Biochem.

    (1989)
  • M.G. Bachem et al.

    Tumor necrosis factor alpha (TNFalpha) and transforming growth factor betal (TGFbeta1) stimulate fibronectin synthesis and the transdifferentiation of fat-storing cells in the rat liver into myofibroblasts

    Virchoff's Arch. B. Cell Pathol.

    (1993)
  • S. Bachmann et al.

    Ultrastructural correlates of liver graft failure from storage injury: studies of graft protection by Carolina rinse solution and pentoxifylline

  • C. Balazs et al.

    Immunological aspects of the effect of pentoxifylline (trental)

    Acta Microbiol. Immunol Hung.

    (1994)
  • J. Barosso-Aranda et al.

    Pentoxifylline pretreatment decreases the pool of circulating activated neutrophils, in-vivo adhesion to endothelium, and improves survival from hemorrhagic shock

    Biorheology

    (1990)
  • D.W. Beelen et al.

    Constant intravenous pentoxifylline infusions in allogenic marrow transplant recipients: results of a dose escalation study

    Bone Marrow Transpl.

    (1993)
  • B Beermann et al.

    Kinetics of intravenous and oral pentoxifylline in healthy subjects

    Clin. Pharmacol. Ther.

    (1985)
  • D.W.A. Beno et al.

    Administratio of prostaglandin E1 analog reduces rat hepatic and ito cell collagen gene expression and collagen accumulation after bile duct ligation injury

    Hepatology

    (1993)
  • G. Berkenboom et al.

    Prevention of cyclosporine A-induced vascular toxicity by pentoxifylline

    J. Cardiovasc. Pharmacol.

    (1991)
  • B. Berman et al.

    Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin

    Br. J. Dermatol.

    (1990)
  • H. Bessler et al.

    Effect of pentoxifylline on the phagocytic activity, CAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells

    J. Leukocyte Biol.

    (1986)
  • D.M. Bissel et al.

    Cell-specific expression of transforming growth factor-beta in rat liver-Evidence for autocrine regulation of hepatocyte proliferation

    J. Clin. Invest.

    (1995)
  • D.K. Biswas et al.

    Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-KB action

    J. AIDS

    (1993)
  • R. Blomhoff et al.

    Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis

    FASEB J.

    (1991)
  • G. Boigk et al.

    Antifibrotic effect of pentoxiphylline in rat biliary fibrosis due to bile duct obstruction

    J. Hepatol.

    (1995)
  • W.A. Border et al.

    Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease

    Nature

    (1992)
  • D. Breuille et al.

    Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis

    Am. J. Physiol.

    (1993)
  • Cited by (116)

    • Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19

      2023, Thrombosis Update
      Citation Excerpt :

      Suppression of neutrophil activation with amplification of IL-10 by pentoxifylline protects against endothelial damage and development of a nidus for coagulation. When modulating leukocyte-endothelium adhesion with complete inhibition of intercellular adhesion molecule-1 expression, it sufficiently regulates leukocyte-platelet interactions relevant in thrombosis [75]. A study of the use of pentoxifylline for lysis of intraperitoneal adhesions in rats demonstrated increased levels and activity of tissue plasminogen activator when compared with a control group [76].

    • Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways

      2019, Life Sciences
      Citation Excerpt :

      Therefore, examining the effect of certain PDE inhibitors in liver fibrosis seemed appealing especially that limited data studying the role of PDEs in the pathogenesis of liver fibrosis are available. Research conducted on PDE inhibitors proved their beneficial effect in experimental liver injuries [14–16]. Among these inhibitors are vinpocetine which is PDE1 inhibitor and roflumilast, a PDE4 inhibitor.

    View all citing articles on Scopus

    We are grateful to Dr. Georg Kirchner, Department of Clinical Chemistry, Philipps-University of Marburg, for reading the manuscript.

    View full text